125 related articles for article (PubMed ID: 6592946)
1. Comparative study of platelet aggregation measured with 3 different methods (photometric and impedance) in ticlopidine treated patients.
Lecrubier C; Girard P; Noire P; Samama M
Agents Actions Suppl; 1984; 15():60-7. PubMed ID: 6592946
[No Abstract] [Full Text] [Related]
2. [Evaluation of platelet aggregation in patients treated with ticlopidine].
Sbalzarini G; Carniti E; Fiorini L; Iezzi BG
Clin Ter; 1984 Nov; 111(3):247-50. PubMed ID: 6240365
[No Abstract] [Full Text] [Related]
3. Ticlopidine and platelet function.
Lecompte T; Lecrubier C; Potevin F; Samama M
Thromb Haemost; 1986 Jun; 55(3):437-8. PubMed ID: 3529484
[No Abstract] [Full Text] [Related]
4. [The antiaggregation effect of ticlopidine on blood platelets preliminary results and prospectives for studies in various diseases].
Andriani A; Chiappetta MG; Fabiani M; Mosiello G; Beni A
Clin Ter; 1983 Feb; 104(3):219-22. PubMed ID: 6345050
[No Abstract] [Full Text] [Related]
5. The influence of ticlopidine on the natural course of retinal vein occlusion.
Houtsmuller AJ; Vermeulen JA; Klompe M; Zahn KJ; Henkes HE; Baarsma GS; Tijssen J
Agents Actions Suppl; 1984; 15():219-29. PubMed ID: 6385648
[TBL] [Abstract][Full Text] [Related]
6. Ticlopidine in the secondary prevention of early diabetes-related microangiopathy: protocol of a multicenter therapeutic study (TIMAD study).
Mirouze J
Agents Actions Suppl; 1984; 15():230-58. PubMed ID: 6385649
[No Abstract] [Full Text] [Related]
7. In vivo effect of ticlopidine on fibrinogen-platelet cofactor activity and binding of fibrinogen to platelets.
Dunn FW; Soria J; Soria C; Thomaidis A; Lee H; Caen JP
Agents Actions Suppl; 1984; 15():97-104. PubMed ID: 6091425
[No Abstract] [Full Text] [Related]
8. Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine.
Bastida E; Escolar G; Almirall L; Ordinas A
Thromb Haemost; 1986 Jun; 55(3):333-7. PubMed ID: 3750263
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo effects of ticlopidine on human platelets: inhibition of fibrinogen binding by a mechanism independent of thromboxane formation.
Iovine C; d'Avenia V; Turco S; Mattioli PL; di Minno G
Agents Actions Suppl; 1984; 15():105-7. PubMed ID: 6592941
[No Abstract] [Full Text] [Related]
10. [The effects of ticlopidine on platelet aggregation: study on 13 atherosclerotic patients].
Lenci R; Galante A; Borzi M; Ariganello M; Sommariva L; Filice A; Cannata D
Clin Ter; 1983 Feb; 104(3):205-9. PubMed ID: 6861457
[No Abstract] [Full Text] [Related]
11. Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
Jakubowski JA; Payne CD; Weerakkody GJ; Brandt JT; Farid NA; Li YG; Naganuma H; Lachno DR; Winters KJ
J Cardiovasc Pharmacol; 2007 Mar; 49(3):167-73. PubMed ID: 17414229
[TBL] [Abstract][Full Text] [Related]
12. Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.
Weerakkody GJ; Jakubowski JA; Brandt JT; Payne CD; Naganuma H; Winters KJ
J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):205-12. PubMed ID: 17875947
[TBL] [Abstract][Full Text] [Related]
13. Antiplatelet drugs and thrombosis prevention: ticlopidine in perspective.
de Gaetano G; Bertelé V
Arq Bras Cardiol; 1983 Dec; 41(6):425-7. PubMed ID: 6678584
[No Abstract] [Full Text] [Related]
14. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A
Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
[TBL] [Abstract][Full Text] [Related]
15. Ticlopidine - an antiplatelet drug: effects in human volunteers.
O'Brien JR; Etherington MD; Shuttleworth RD
Thromb Res; 1978 Aug; 13(2):245-54. PubMed ID: 694843
[No Abstract] [Full Text] [Related]
16. Measurement of platelet aggregation during antiplatelet therapy in ischemic stroke.
Pongrácz E
Clin Hemorheol Microcirc; 2004; 30(3-4):237-42. PubMed ID: 15258349
[TBL] [Abstract][Full Text] [Related]
17. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin.
Lecrubier C; Conard J; Horellou MH; Samama M
Agents Actions; 1983 Feb; 13(1):77-80. PubMed ID: 6858789
[TBL] [Abstract][Full Text] [Related]
18. Effect of N-(3-hydroxy-1,3,5,(10)estratrien-17 beta-yl)-3-hydroxypropyl-amine (prolame) and estradiol-17 beta on platelet aggregation.
Baños G; De la Peña A; Izaguirre RR; Mandoki JJ; Mendoza-Patiño N; Rubio-Póo C; Fernández JM
Proc West Pharmacol Soc; 1991; 34():79-83. PubMed ID: 1788347
[No Abstract] [Full Text] [Related]
19. A possible method to control prolongations of bleeding time under antiplatelet therapy with ticlopidine.
Thébault J; Blatrix C; Blanchard J; Panak E
Thromb Haemost; 1982 Aug; 48(1):6-8. PubMed ID: 7135344
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function.
Picard-Fraire C
Agents Actions Suppl; 1984; 15():68-75. PubMed ID: 6385655
[No Abstract] [Full Text] [Related]
[Next] [New Search]
